Literature DB >> 22503536

A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.

John M Akudugu1, Roger W Howell.   

Abstract

UNLABELLED: There is considerable interest in the use of α-emitting radionuclides in radioimmunotherapy. However, the high toxicity of α-emitting radionuclides often does not permit administration of high activities for fear of normal tissue toxicity. Accordingly, targeting procedures need to be optimized for improved tumor control and minimized normal tissue toxicity. To guide design of effective cocktails of α-emitting radiopharmaceuticals and chemotherapy drugs, approaches that can predict biological response of a cell population on a cell-by-cell basis are needed.
METHODS: Cells were concomitantly treated with the α-particle emitting radiochemical (210)Po-citrate and daunomycin, or with (210)Po-citrate and doxorubicin. The responses of the treated cell populations were measured with a colony forming assay. The nonuniform cellular incorporation of the radiochemical and drugs was determined simultaneously on a cell-by-cell basis using flow cytometry. Monte Carlo methods were used to simulate cell survival on the basis of individual cell incorporation of each cytotoxic agent and validated by direct comparison with the experimental clonogenic cell survival.
RESULTS: Both daunomycin and doxorubicin enhanced the toxicity of the α-particles with a magnitude greater than expected based on single-agent toxicities. Cell survival obtained by Monte Carlo simulation was in good agreement with clonogenic cell survival for the combination treatments.
CONCLUSION: Flow cytometry assisted Monte Carlo simulations can be used to predict toxicity of cocktails of α-emitting radiopharmaceuticals and chemotherapy drugs in a manner that takes into account the effects of nonuniform distributions of agents within cell populations.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22503536      PMCID: PMC3399932          DOI: 10.1016/j.nucmedbio.2012.01.011

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  42 in total

1.  Tracking bismuth antiulcer drug uptake in single Helicobacter pylori cells.

Authors:  Cheuk-Nam Tsang; Koon-Sing Ho; Hongzhe Sun; Wing-Tat Chan
Journal:  J Am Chem Soc       Date:  2011-04-25       Impact factor: 15.419

Review 2.  Radioimmunotherapy of solid tumors: searching for the right target.

Authors:  Hong Song; George Sgouros
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Changes in lognormal shape parameter guide design of patient-specific radiochemotherapy cocktails.

Authors:  John M Akudugu; Prasad V S V Neti; Roger W Howell
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

4.  Lognormal distribution of cellular uptake of radioactivity: Monte Carlo simulation of irradiation and cell killing in 3-dimensional populations in carbon scaffolds.

Authors:  Didier Rajon; Wesley E Bolch; Roger W Howell
Journal:  J Nucl Med       Date:  2011-05-13       Impact factor: 10.057

5.  Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs.

Authors:  John M Akudugu; Roger W Howell
Journal:  Int J Radiat Biol       Date:  2011-12-09       Impact factor: 2.694

6.  Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.

Authors:  G A Wiseman; C A White; M Stabin; W L Dunn; W Erwin; M Dahlbom; A Raubitschek; K Karvelis; T Schultheiss; T E Witzig; R Belanger; S Spies; D H Silverman; J R Berlfein; E Ding; A J Grillo-López
Journal:  Eur J Nucl Med       Date:  2000-07

7.  Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.

Authors:  Danny L Costantini; Daniela F Villani; Katherine A Vallis; Raymond M Reilly
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

8.  MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Authors:  George Sgouros; John C Roeske; Michael R McDevitt; Stig Palm; Barry J Allen; Darrell R Fisher; A Bertrand Brill; Hong Song; Roger W Howell; Gamal Akabani; Wesley E Bolch; A Bertrand Brill; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels; Pat B Zanzonico
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

Review 9.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.

Authors:  M Gerlinger; C Swanton
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

View more
  2 in total

1.  Survival of tumor and normal cells upon targeting with electron-emitting radionuclides.

Authors:  Didier Rajon; Wesley E Bolch; Roger W Howell
Journal:  Med Phys       Date:  2013-01       Impact factor: 4.071

Review 2.  Dosimetry for radiopharmaceutical therapy.

Authors:  George Sgouros; Robert F Hobbs
Journal:  Semin Nucl Med       Date:  2014-05       Impact factor: 4.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.